| Name | Title | Contact Details |
|---|
Ceres Inc is a Newbury Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Redmond and Greer Pharmacy Supply is a new and motivated corporation with many iconic brands in our portfolio. Our company began much like many independent pharmacies do, as a family business. Over a short time, the family business evolved into what is now one of the nation`s largest suppliers of niche market prescription medications and related products. Growing is at our heart and products are always changing use our expertise to make sure you`re on the forefront of these new products. Redmond and Greer Pharmacy Supply is a division of The Coney Consulting Group, LLC Our MISSION Our focus is providing value to our customers. We drive value to independent pharmacies by navigating the constantly changing business environment and keeping them in front of new products and profitable opportunities. Our VISION To be the preferred secondary wholesaler to the independent pharmacy market. Our VALUES Being pharmacist owned, we are highly focused on growing the business of the independent pharmacy. Our customers deserve the best, and to provide the best, we deliver all the tools a pharmacy needs to succeed – comprehensive product knowledge, access to pharmaceutical drugs at the best price, and a team that puts service and compliance above all else.
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie`s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie`s mission is to revolutionize the use of radiomedicines in cancer.
AxelaCare Health Solutions is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Heron Therapeutics is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action. The Company's lead product, SUSTOL™ (formerly APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. Heron Therapeutics received a Complete Response Letter to its SUSTOL New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration during the fourth quarter of 2014. Heron Therapeutics' core Biochronomer technology, on which SUSTOL and its other products are based, consists of bioerodible polymers designed to release drugs over a defined period of time. The Company has completed over 100 in vivo and in vitro studies demonstrating that its Biochronomer technology is potentially applicable to a range of therapeutic areas, including prevention of nausea and vomiting, pain management, control of inflammation and treatment of ophthalmic diseases. Heron Therapeutics has also completed comprehensive animal and human toxicology studies that have established that its Biochronomer polymers are generally well tolerated. Furthermore, the Company's Biochronomer technology can be designed to deliver drugs over periods varying from days to several months. In addition to its lead drug candidate SUSTOL, Heron Therapeutics has a pipeline of other product candidates that use the Biochronomer technology.